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Transforming growth factor-βPatients with Marfan syndrome (MFS) are at high risk of life-threatening aortic dissections. The condition is
caused by mutations in the gene encoding ﬁbrillin-1, an essential component in the formation of elastic ﬁbers.
While experimental ﬁndings in animal models of the disease have shown the involvement of transforming
growth factor-β (TGF-β)- and angiotensin II-dependent pathways, alterations in the vascular extracellularmatrix
(ECM) may also play a role in the onset and progression of the aortic disease. Lysyl oxidases (LOX) are extracel-
lular enzymes, which initiates the formation of covalent cross-linking of collagens and elastin, thereby contribut-
ing to the maturation of the ECM. Here we have explored the role of LOX in the formation of aortic aneurysms in
MFS. We show that aortic tissue from MFS patients and MFS mouse model (Fbn1C1039G/+) displayed enhanced
expression of themembers of the LOX family, LOX and LOX-like 1 (LOXL1), and this is associatedwith the forma-
tion of mature collagen ﬁbers. Administration of a LOX inhibitor for 8 weeks blocked collagen accumulation and
aggravated elastic ﬁber impairment, and these effects correlated with the induction of a strong and rapidly
progressing aortic dilatation, and with premature death in the more severe MFS mouse model, Fbn1mgR/mgR,
without any signiﬁcant effect onwild type animals. This detrimental effect occurred preferentially in the ascend-
ing portion of the aorta,with little or no involvement of the aortic root, andwas associated to an overactivation of
both canonical and non-canonical TGF-β signaling pathways. The blockade of angiotensin II type I receptor with
losartan restored TGF-β signaling activation, normalized elastic ﬁber impairment and prevented the aortic dila-
tation induced by LOX inhibition in Fbn1C1039G/+ mice. Our data indicate that LOX enzymes and LOX-mediated
collagen accumulation play a critical protective role in aneurysm formation in MFS.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Marfan syndrome (MFS) is an autosomal dominant connective
tissue disorder caused by mutations in the gene encoding ﬁbrillin-1
(FBN1), an essential component in the formation of elastic ﬁbers [1,2].
The disorder has pleiotropicmanifestations in the skeletal (overgrowth),cular “Severo Ochoa”, Consejo
ersidad Autónoma de Madrid
+34 91 196 4505; fax: +34 91
Pascual).
zález-Santamaría contributed
as co-corresponding authors.ocular (lens luxation) and cardiovascular (progressive proximal aorta di-
latation and mitral valve prolapse) systems. Prognosis of MFS is
dominated by the cardiovascular phenotype, with a high risk of
life-threatening aortic dissection.
Although the pathogenesis of the aortic disease could be explained
by simple tissue alteration imposed by defective assembly of elastin
into elastic ﬁbers, recent investigations have shown a more complex
scenario, with involvement of transforming growth factor-β (TGF-β)-
and angiotensin II-dependent pathways, as well as matrix-dependent
alterations [3–6]. To further complicate matters, the aortic phenotype
of MFS patients vary widely, with small aneurysms that rupture very
soon whereas other larger dilatations remain asymptomatic, even
among family members harboring the same FBN1 mutation [7]. These
observations suggest that epistatic interactions with other factors
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dates for such modiﬁers is of clinical interest. While the search for such
genes has been focused on those co-expressed with FBN1 in mouse
aorta, without a clear deﬁnition of those being directly implicated in
the progression of aortic dilatations, genes involved in the process of
aortic remodeling, especially those belonging to the ECM or ECM-
remodeling categories constitute highly attractive candidates [8]. Partic-
ularly interesting is the case of the lysyl oxidase (LOX) family of matrix
remodeling enzymes. These enzymes, for which ﬁve members have
been described in mammals (the canonical LOX, and four LOX-like
from 1 to 4), catalyze the conversion of lysine and hydroxylysine groups
of collagen and elastin into highly reactive aldehydes, which eventually
condense with other aldehyde group or intact lysine residue to form a
variety of inter- and intrachain cross-linkages [9]. LOX family members
are essential factors for the maturation of the ECM as evidenced in
mousemodels deﬁcient in LOX and LOXL1, and in experimental models
under pharmacological inhibition of LOX enzymatic activity, whichhave
been shown to display defective ECM [10–13]. Interestingly, both genet-
ic and pharmacological inactivation of LOX enzymatic activity is linked
to cardiovascular malformations, evidences that support a fundamental
role of LOX family members in vascular ECM homeostasis.
In the context of MFS, conﬂicting reports exist on the contribution of
LOX to aortic pathology. Early work reported that elastin cross-linking
was reduced in the aorta of MFS patients as compared to healthy sub-
jects [14]. However, other studies did not ﬁnd any signiﬁcant alteration
in LOX activity or LOXmRNA in skinﬁbroblasts or vascular smoothmus-
cle cells isolated and cultured fromMFS patients [15,16]. More recently,
defects in collagen microarchitecture (higher collagen content andFig. 1. Enhanced expression of LOX and LOXL1 and accumulation of mature collagenmatrix in
MFS (n=16) human ascending aortic tissue stained for elasticﬁberswith Verhoeff–VanGieson
LOX and LOXL1 by immunohistochemistry. Left (4× magniﬁcation). Right (10× magniﬁcation
areas showing immunostaining for LOX and LOXL1. Scale bar: 0.5 mm.increased collagen cross-linking), together with increased tissue stiff-
ness have been reported in the aneurysms of MFS mice [17]. Therefore,
the question of whether LOX enzymes are involved in aortic disease
progression of MFS still remains unclear. To address this issue, we
have characterized the expression of LOX isoforms in aortic tissue of
MFS patients and mice, and analyzed their impact on aneurysm forma-
tion in animal models of the disease.
2. Results
2.1. LOX and LOXL1 expression is upregulated in aortic tissue fromMFS pa-
tients and in a MFS mouse model
Surgical specimens from the ascending aorta of 16 patients (clinical
characteristics in Supp. Table 1) were analyzed by immunohistochem-
istry for the expression of LOX isoforms (LOX and LOX-like 1 to 4) as
well as for elastic ﬁber and collagen architecture visualized by
Verhoeff–VanGieson's (VVG) and Picrosirius red (PSR) staining, respec-
tively. Normal thoracic aortas were retrieved from 8 organ transplant
donors. As shown in Fig. 1, aneurysmal tissue from MFS patients
displayed disorganized elastic network and collagen ﬁber accumulation
and disorder as compared with healthy aorta. Interestingly, collagen
visualization by PSR under polarized light showed evident positive bire-
fringence in MFS medial aorta; in marked contrast to normal aorta,
which displayed an almost black background. While the presence of
positively birefringent collagen scaffolds does not directly demonstrate
enhanced cross-linking, these observations indicate the potential in-
volvement of LOX upregulation in the formation of mature collagenthe aorta fromMFS patients. Representative micrographs from healthy donor (n = 8) and
(VVG), for collagenwith Picrosirius red (PSR) under brightﬁeld and polarized light, and for
). Arrows indicate the presence of elastic ﬁber defects, ﬁbrillar collagen, as well as medial
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showed enhanced expression of LOX and LOXL1 in the aortic medial
layer of MFS patients compared to normal aorta (Fig. 1). We did not
ﬁnd differential expression of the remaining isoforms of LOXL (LOXL2-
4) in MFS versus normal aorta (data not shown). We conﬁrmed the up-
regulation of LOX isoform by immunoblotting using protein extracts
isolated from healthy andMFS aorta (Supp. Fig. 1A). Available antibod-
ies for the LOXL1 did not work for immunoblotting in our hands (data
not shown). Aorta tissues were also used for determination of LOX ac-
tivity by H2O2 production with Amplex Red. While speciﬁc activity
could not be detected in extracts isolated from healthy aorta, samples
from MFS patients showed measurable levels of enzymatic activity
(Supp. Fig. 1B). Additionally, medial areas of MFS and control aorta sec-
tions were laser-capture microdissected and RNA extracted from these
tissue portions. As shown in Supp. Fig. 1C, MFS samples showed en-
hanced mRNA expression of LOX and LOXL1 compared with controls,
in agreement with the results obtained by immunohistochemistry.
The expression of LOX isoforms and their associationwith alterations
in elastic ﬁber and collagen network were also studied in a MFS mouse
model. As previously reported, proximal ascending aorta ofmice hetero-
zygous for amissensemutation in Fbn1 gene (Fbn1C1039G/+), a validated
animal model of MFS [18], displayed signiﬁcant elastic ﬁber fragmenta-
tion (Fig. 2A). Compared to wild type (WT), MFS mice showed evident
collagen deposition, which, in analogy with MFS patients, displayed
increased content of mature collagen, as visualized by PSR staining
under polarized light. The ECM structural alterations observed in MFS
mice occurred with upregulation of LOX protein, as assessed by immu-
nohistochemistry and immunoblotting (Fig. 2A and B). These analyses
are only shown for LOX, as the available antibody for LOXL1 did not
function in mouse aortic tissue samples. Additionally, MFS mice aorta
showed enhancedmRNAexpression of Lox and Loxl comparedwith con-
trols (Fig. 2C). These ﬁndings indicate that the expression of LOX andFig. 2. Collagen deposition and LOX expression in aneurysmal tissue from Marfan mouse m
Fbn1C1039G/+ (C1039G/+, n= 3)mice stained for elastic ﬁbers with Verhoeff–Van Gieson (VVG
by immunohistochemistry. Arrows indicate the presence of elastic ﬁber defects, ﬁbrillar co
(B) Immunoblotting for detection of LOX protein in total extracts from wild type (WT, n = 4)
LOX and β-actin (loading control). (C) Lox and Loxl1mRNA expressionmeasured by real time q
are means + SEM. *P b 0.05.LOXL1 isoforms is increased in aneurysmal tissues from MFS patients
and in amousemodel of thedisease, in associationwith enhanced depo-
sition of mature collagen in the tunica media.
2.2. Inhibition of LOX activity induces the dilatation of the ascending aorta
in MFS mouse models
In order to test whether the increased expression of LOX isoforms in
the diseased aorta plays a signiﬁcant role in aneurysmal formation,
Fbn1C1039G/+ mice were treated with β­aminopropionitrile (BAPN), a
compound shown to irreversibly inhibit LOX activity in vitro and
in vivo [19]. As shown in Fig. 3A and B, inhibition of LOX enzymatic ac-
tivity signiﬁcantly attenuated the formation of mature birefringent col-
lagen ﬁbers in the medial layer of MFS mice as assessed by PSR under
polarized light. Consistently, evaluation of LOX enzymatic activity by
Amplex Red showed that MFS mice displayed higher values compared
to wild type animals, and that they were signiﬁcantly reduced by
BAPN administration (Fig. 3C). We have also determined the levels of
collagen cross-links (HPLC) and total collagen (colorimetric hydroxy-
proline assay). As shown in Fig. 3D, MFS mice displayed a modest
though signiﬁcant increase in hydroxylysylpyridinoline (HP) levels as
compared to wild type. LOX inhibition with BAPN normalized the
amount of cross-links to control levels. Levels of lysyl pyridinoline
cross-links,which are usually about ten times lower thanHP inmost tis-
sues, were below detection level in mouse samples under our experi-
mental conditions (data not shown). Biochemical determination of
total collagen revealed a higher content in MFS compared to wild type
mice, and a signiﬁcant reduction in BAPN-treatedMFSmice, an observa-
tion indicating that LOX-mediated activity is required for collagen depo-
sition in aorta (Fig. 3E). We then studied the progression of aortic
aneurysm by echocardiogram after 4 and 8 weeks of BAPN treatment
(Fig. 4A andB). LOX inhibition induced a strong and rapidly progressingodel Fbn1C1039G/+. (A) Representative micrographs from wild type (WT, n = 3) and
), for collagenwith Picrosirius red (PSR) under brightﬁeld and polarized light, and for LOX
llagen, as well as medial areas showing immunostaining for LOX. Scale bar: 0.05 mm.
and Fbn1C1039G/+ (C1039G/+, n = 4). Representative gel assayed with antibodies against
uantitative RT-PCR in ascending aortas fromWT (n= 3) and Fbn1C1039G/+ (n= 3). Values
Fig. 3. Inhibition of LOX enzymatic activity diminishes the accumulation of collagen and collagen cross-links in the ascending aorta of MFS mice Fbn1C1039G/+. (A) Mature collagen (PSR
under polarized light) in the proximal ascending aorta of WT and Fbn1C1039G/+ mice treated with β-aminopropionitrile (BAPN, daily intraperitoneal injection, 300 mg/kg) or placebo
for 8 weeks: WT (n = 3), WT + BAPN (n = 3) Fbn1C1039G/+ (n = 3) and Fbn1C1039G/++BAPN (n = 3). Arrows indicate the presence of birefringent ﬁbrillar collagen. Scale bar:
0.05 mm. (B) Quantitative analysis of the presence of mature collagen ﬁbers visualized by PSR staining under polarized light shown in (A). Biochemical measurements of LOX activity
(Amplex red, C), total collagen (hydroxyproline, colorimetric, D), and mature cross-link hydroxylysylpyridinoline (HP) levels (HPLC, E) in aorta samples from WT (n = 3),
WT + BAPN (n = 3) Fbn1C1039G/+ (n = 3) and Fbn1C1039G/++BAPN (n = 3). Values are expressed as pmol H2O2 generated per mg protein in 60 min reaction time (LOX activity), μg
(total collagen) and pmol (crosslinks, HP) per mg wet tissue. Values are mean ± SEM. *p b 0.05.
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compared to baseline values, without any signiﬁcant effect on WT ani-
mals. Interestingly, BAPN treatment impacted the ascending aorta di-
ameter in this mouse models in the absence of a signiﬁcant effect onFig. 4. Inhibition of LOX enzymatic activity induces the formation of ascending aorta aneurysm
echocardiography prior to the beginning of the treatment (baseline), and after 4 and 8 weeks o
(n = 9) and Fbn1C1039G/++BAPN (n = 9). Values are means + SEM. *P b 0.05. (B) Represen
8 weeks of treatment. Arrows indicate the dimension of the ascending aorta. Scale bars: 1 mm.the aortic root, which progressively dilated in MFS mice, but whose
rate was not modiﬁed by LOX inhibition. Morphometric analyses of
aorta at the end of the 8-week in vivo trial conﬁrmed the echocardio-
graphic observations (Fig. 4C). We have then investigated whethers in MFS mice Fbn1C1039G/+. A) Aortic root and ascending aorta diameter as measured by
f the administration of BAPN or placebo: WT (n = 9), WT + BAPN (n = 9) Fbn1C1039G/+
tative parasternal long axis echocardiographic systolic images of the aorta of mice after
(C) Gross morphology of representative aortas from mice after 8 weeks of treatment.
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tic root versus the ascending aorta that might explain the response of
these aorta portions to LOX inhibition. Histological analysis of the elastic
ﬁber network shows that BAPN administration affected mainly the as-
cending aorta, with less involvement of the root (Fig. 5A and B). TGF-
β-dependent signaling pathways have been invoked to be implicated
in the pathogenesis of the MFS aortic disease [3–6]. Therefore, we
have investigated whether LOX inhibition altered the extent of activa-
tion of both canonical (Smad-dependent) and non-canonical (ERK-de-
pendent) TGF-β signaling pathways. As shown also in Fig. 5C and D,
BAPN administration induced a signiﬁcant increase in both phospho-
Smad2 and phospho-ERK1/2 in the ascending aorta, but not in the
root. We have also analyzed whether BAPN administration altered the
expression of collagen genes (Col1a1 and Col3a1), as well as matrix
metalloproteases (Mmp2 and Mmp9) and its inhibitor Timp4, some of
them reported to be abnormally expressed in aneurysmal tissues [20].
Except for Col1a1, which was signiﬁcantly upregulated by BAPN in
MFS mice, but not in wild type, the expression of the remaining genes
remained essentially unchanged (Supp. Fig. 2). We have also analyzed
the effect of LOX inhibition in homozygousmgRmice, amore aggressive
MFS model with hypomorphic expression of FBN1 protein [21]. As
shown in Fig. 6A–C, mgRmice also reproduced the aortic phenotype in-
duced by inhibition of LOX activity: a progressive growth of ascending
aorta as observed after 4 and 8 weeks of BAPN administration. Similarly
to Fbn1C1039G/+mice, BAPN did not signiﬁcantly modiﬁed the rate of di-
latation of aortic root in the mgR model (Supp. Fig. 4). In consistence
with these results, LOX inhibitor sharply shortened the survival of ho-
mozygous mgR mice as compared with animals treated with vehicle
(Fig. 6D). Post-mortem macro- and microscopic examination of mgR
mice under placebo and BAPN treatment has revealed that BAPN accel-
erated the deterioration of the aorta, and, interestingly, precipitated the
development of the cardiomyopathy, a typical manifestation of this
model of the disease (Supp. Fig. 3) [22].Fig. 5. Effect of LOX inhibition on elastic ﬁber network and canonical and noncanonical TGF-β
staining) organization in the root and ascending aorta ofWT and Fbn1C1039G/+mice treatedwith
Fbn1C1039G/++BAPN (n= 3). Arrows indicate the presence of elastic ﬁber defects. Scale bar: 0.
lower panel: ascending). C) Immunoblotting analysis of phospho-Smad2 (p-SMAD2) and p
WT + BAPN (n = 3) Fbn1C1039G/++Placebo (n = 3) and Fbn1C1039G/++BAPN (n = 3) mice. (2.3. The angiotensin II receptor blocker, losartan prevents aortic dilatation
induced by LOX inhibition in MFS mice
The blockade of angiotensin II type I receptor (AT1R) has been
shown to reduce aortic dilatation in MFS mice, and this observation is
the basis of the clinical use of this drug to halt or slowdown the progres-
sion of aneurysmal disease in MFS patients [23–25]. We studied the
effect of losartan on BAPN-mediated aortic disease exacerbation in
Fbn1C1039G/+ mice. As shown in Fig. 7A, losartan treatment prevented
the ascending aorta dilatation induced by LOX inhibition in MFS mice.
Histological examination by VVG staining revealed that losartan admin-
istration normalized elastic ﬁber fragmentation in vehicle or BAPN-
treated MFS mice (Fig. 7B and C). We have also analyzed the extent of
collagen maturation in animals treated with BAPN and losartan. As
shown in Fig. 7B and D, treatment with losartan on top of BAPN did
not modify the collagen matrix, which appears essentially the same as
in the BAPNonly group or inwild type animals. The extent of the activa-
tion of both canonical Smad2 and non-canonical ERK TGF-β-dependent
signaling pathwayswas studied by immunohistochemistry inMFSmice
treated with BAPN and losartan. As shown in Fig. 7E, losartan adminis-
tration restored thebasal levels of activation of both signalingpathways.3. Discussion
Themost serious complications associated with MFS involve the de-
velopment of life-threatening thoracic aortic aneurysms. While experi-
mental ﬁndings in animal models of the disease have indicated the
involvement of TGF-β- and angiotensin II-dependent pathways, as
well as the contribution of matrix-dependent effects or augmentedme-
chanical stress, a complete picture about the pathogenetic mechanism
driving the onset and progression of the aortic disease has not been
achieved. In the context of the mechanobiology, the aortic ECM hassignaling in the root and ascending aorta of MFS mice Fbn1C1039G/+. (A) Elastic ﬁber (VVG
BAPN or placebo for 8weeks:WT (n=3),WT+BAPN (n=3) Fbn1C1039G/+ (n=3) and
05mm. B) Elastic ﬁber organization score as assessed by VVG staining (upper panel: root;
hospho-ERK1/2 (p-ERK1/2) in the root and ascending aorta of WT + Placebo (n = 3),
C) Protein band intensities normalized to β­actin. Values are means + SEM. *P b 0.05.
Fig. 6. LOX inhibition induces ascending aortic dilatation and reduces survival in homozygous mgR mice. (A) Ascending aortic diameter as measured by echocardiography prior to the
beginning of the treatment (baseline), and 4 and 8 weeks after the administration of BAPN or placebo in homozygous mgR mice: mgR (n = 9) and mgR + BAPN (n = 9). Values are
means + SEM. *P b 0.05. (B) Representative parasternal long axis echocardiographic systolic images of the ascending aorta of mgR and mgR + BAPN mice after 8 weeks of treatment.
Arrows denote ascending aorta dimension. Scale bar: 1 mm. (C) Gross morphology of representative aortas of mgR and mgR + BAPN mice. (D) Kaplan–Meier survival curve showing
diminished life span of mgR + BAPN as compared with mgR group.
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mechanical loading [26,27]. Main components of vessel wall ECM in-
clude elastin and collagen, which are responsible for the properties of
recoil and strength, respectively, typical of a healthy aorta [28]. Both
collagen and elastin ﬁbers must be cross-linked in order to exhibit
these properties, observations that support the notion that LOX family
members are essential factors for the maturation of the ECM [29].
Herewe report that the aorta ofMFS patients andmousemodels dis-
plays increased expression of LOX and LOXL1 isoforms. These results are
in agreement with a previous evidence of elevated levels of non-
reducible lysyl oxidase-initiated collagen cross-links (hydroxylysyl
pyridinoline/lysyl pyridinoline cross-links) in the aorta from MFS pa-
tients, though the increase in the expression of LOX isoforms had not
been previously reported [17]. Increased expression levels of LOX corre-
late with enhanced deposition of mature collagen ﬁbers within the
media layer. In fact, togetherwith the presence of severe elastic lamellar
disruption, a common histopathological pattern consistently found in
MFS is the accumulation of collagenous material, and a concomitant
increase in tissue stiffness [30–33]. To this respect, we have recently re-
ported that vascular smoothmuscle cells isolated from the aorta of MFS
patients display increased cell and matrix stiffness as a result of in-
creased expression of contractile proteins and collagen [34]. While it is
usually assumed that collagen deposition and stiffness are features of
the disease, it is still unknown whether they are a consequence of
chronic damage, being the substrate for the dilatation and further rup-
ture, or constitute an active response opposing pathological remodeling.
This has in fact important clinical implications as the measurement of
aortic stiffness has been largely used for diagnosis and prognosis in af-
fected individuals, though some recent clinical studies claimed that in-
creased aortic stiffness is associated with slower rate of aneurysm
progression rather than with augmented dilatation and rupture risk
[32,33]. Our data may shed light on this controversy as we found that
the disruption of the accumulation of ﬁbrillar collagen by inhibition of
LOX activity induces the development of aortic aneurysms in MFS
mice. In consistence with these results, a case report described a spon-
taneous arterial wall dissection associated with ECM disorganization
and dramatically reduced LOX expression [35]. Therefore, our results in-
deed indicate that collagen deposition and cross-linking constitute a
beneﬁcial response against tissue deformation, with LOX enzymes
playing a critical role in this action.
In our study, inactivation of LOX activity is achieved by the use of the
broad inhibitor, BAPN [19]. Interestingly, at the dosage (300mg/kg) and
time (amaximum of 8 weeks) regime used in our study, we did not ob-
serve any particular effect on the aorta of wild type animals, suggesting
that MFS mice are somehow predisposed to the formation of ascendingaorta lesions. Noteworthy, recent evidences have shown that infusion
of BAPN induces aortic aneurysm and rupture in mice only in conjunc-
tion of hypertension, either by administration of angiotensin II or
deoxycorticosterone acetate (DOCA)-salt [10,13]. These observations
indicate the requirement of an alteration in the vascular ECM together
with an increase in the hemodynamical loading as a necessary combina-
tion for the development of the aortic dilatation. We propose that the
factor predisposing the aorta ofMFSmice to develop ascending aorta di-
latations under LOX inhibition is the existence of increased mechanical
stress, presumably due to an elastically impaired ECM. Interestingly, and
very consistent with the echocardiographic and histological analyses,
this effect was more evident in the ascending portion of the aorta than
in the root. Although other explanations are feasible, such as the differ-
ent embryonic origin for smooth muscle cells populating these aorta
portions [36], the fact that LOX inhibition preferably affects the ascend-
ing aorta further supports the notion that mechanical stress is a funda-
mental driver of the disease, as it receives the highest impact from the
blood pressure. In fact, this observation is highly reminiscent of the aor-
tic pathology usually found in bicuspid aortic valve (BAV) patients,
where hemodynamic derangements have been proposed to cause alter-
ations in the ascending aorta, and suggests that collagen and collagen
crosslinking play an important role in providing this segment of the
aorta with the mechanical properties required to withstand with the
hemodynamic load [37]. Taken together, our model may be conceived
as an association of MFS and BAV, a human condition that has been
reported to result in a more severe aortic involvement, with a higher
percentage of patients requiring surgical intervention [38].
Considering thematrix-supporting role of LOX enzymes, the delete-
rious effect of LOX inhibition on aneurysmal progression might directly
be explained by deﬁcient matrix cross-linking and subsequent impair-
ment of tissue integrity. We have nevertheless explored whether LOX
inhibition may alter signaling pathways directly involved in the devel-
opment of thoracic aortic aneurysms, in particular TGF-β-dependent
pathways [3–6]. Here we show that LOX inhibition results in an
overactivation of both canonical (Smad) and non-canonical (ERK)
TGF-β-signaling pathways, indicating that LOX or LOX-remodeled ma-
trix is an exquisite regulator of TGF-β signaling activation. We also
show that AT1R antagonism with losartan prevents BAPN-mediated
aorta deterioration, while restoring basal levels of activation of TGF-β-
dependent pathways. The fact that losartan show effectiveness in
preventing aortic disease in MFS mice with or without inhibition of
LOX activity positions the AT1R as a central receptor in the pathogenetic
route leading to aortic aneurysms. Although still a matter of controver-
sy, current hypotheses on aortic aneurysm pathogenesis in MFS invoke
mechanosignaling-dependent pathways, such as angiotensin II/AT1R
Fig. 7. Angiotensin II type 1 receptor (AT1R) blocker, losartan abolishes LOX-mediated exacerbation of aortic phenotype and TGF-β signaling in Fbn1C1039G/+ mice. (A) Ascending aorta
diameter asmeasured by echocardiographyprior to the beginning of the treatment (baseline), and after 8weeks of the administration of BAPNwith andwithout theAT1Rblocker losartan
(in drinkingwater, 0.6 g/L) inWT and Fbn1C1039G/+mice:WT+Placebo (n=9),WT+BAPN (n=9),WT+BAPN+Losartan (n=9), Fbn1C1039G/++Placebo (n=9), Fbn1C1039G/++BAPN
(n= 9), Fbn1C1039G/++BAPN (n= 9)+ Losartan. Values aremeans+ SEM. *P b 0.05. (B) Representativemicrographs fromWT and Fbn1C1039G/+mice treated with placebo or BAPN in the
absence or presence of losartan for 8weeks (n=9) stained for elasticﬁberswith Verhoeff–Van Gieson (VVG) and for collagenwith Picrosirius red (PSR, polarized light). Arrows indicate the
presence of elasticﬁber defects and accumulation ofﬁbrillar collagen. Scale bar: 0.05mm. C) Elasticﬁber organization score as assessed byVVGstaining shown in (B). D)Quantitative analysis
of the presence of mature collagen ﬁbers visualized by PSR staining under polarized light shown in (B). Values are means + SEM. *P b 0.05. E) Immunohistochemical analysis of
canonical (p-SMAD2) and noncanonical (p-ERK1/2) TGF-β signaling in WT and Fbn1C1039G/+ mice treated with placebo or BAPN in the absence or presence of losartan (n = 9).
Arrows indicate the presence of medial areas showing immunostaining for p-SMAD2 and p-ERK1/2. Scale bar: 0.05 mm.
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progression [6,26,27,39]. Based on thismodel, LOX inhibitionmay result
in aggravation of the aortic pathology by two independentmechanisms.On one hand, LOX inhibition might cause worsening of the aortic
phenotype by weakening of the ECM and therefore augmentation
of the hemodynamic stress and subsequent TGF-β signaling and
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might therefore play an entirely unanticipated protective role by
limiting signaling events leading to the pathological remodeling.
An alternative explanation is based on recent in vitro and in vivo ev-
idences suggesting a direct role for LOX in the control of active TGF-β
through a regulatory TGF-β/LOX feedback loop [40,41]. Considering
this potential mechanism, reported to be essential for the regulation
of matrix deposition during skeletal muscle development, LOX inhi-
bition would rise to enhanced TGF-β levels, and subsequently to a
potentiation of its detrimental effects. In one way or another, by in-
hibition of the mechanosensor AT1R, losartan uncouples the driving
force of the pathogenetic process, restoring basal levels of TGF-β-
dependent pathways, and rendering the process not inﬂuenced by
LOX inhibition.
In conclusion, our work supports a protective role for LOX enzymes
in the development of aneurysms in MFS. Althoughmore experimenta-
tion is required, based on our results, LOX and LOXL1 genesmay be con-
sidered as a potential modiﬁer of the phenotype of MFS, so that high
levels of LOX/L expression might stabilize aneurysms whereas low
levels may be associated to increased risk of aortic rupture. LOX
isoforms are extracellularly secreted and can therefore be measured in
serum samples as an index of tissue expression [42]. Therefore, LOX
may be used as a prognostic biomarker in MFS and this aspect is
currently being investigated.
4. Materials and methods
4.1. Patients
Aortic tissue was obtained at the time of surgery from patients with
Marfan syndromeundergoing repair of an aortic aneurysmor dissection
in the Marfan Unit of Hospital Universitario “12 de Octubre”, Madrid
(Spain). All patients met established diagnostic criteria based on the re-
vised Ghent nosology [43]. Normal thoracic aortas from organ donors
for heart transplantation were obtained from the same hospital (see
Supp. Table 1 for clinical data). Segments of aortic tissue (approximate-
ly 2 × 2 cm) were excised at surgery and either ﬁxed in 10% buffered
formalin. Removed samples were embedded in parafﬁn wax and proc-
essed for histological, immunohistochemical and gene expression stud-
ies. The clinical study was approved by the Ethics Committee at the
Hospital Universitario 12 de Octubre, and patients were included after
providing informed, written, and signed consent.
4.2. Mice
All mice were cared for under strict compliance with the Animal
Care andUse Committee of the JohnsHopkinsUniversity School ofMed-
icine. Mouse lines, Fbn1C1039G/+ and mgR, with mutations in the Fbn1
gene, were used as validated MFS animal models [18,21]. Both lines
were maintained on a C57BL/6 background, allowing for valid compar-
isons. In order to further accommodate the potential for temporal- or
background-speciﬁc variation in genetic or pharmacological manipula-
tion experiments, all comparisons were made between contemporary
littermates. Animals were checked daily and all mice found dead were
immediately necropsied to assess for evidence of aortic dissection.
Mice were killed with an inhalation overdose of halothane (Sigma-
Aldrich, St. Louis). Mice underwent immediate laparotomy, descend-
ing abdominal aortic transection, and Phosphate-Buffered Solution
(PBS, pH 7.4) infusion through the left ventricle to ﬂush out the blood.
Mice for aortic histology had latex (Ward's Natural Science, Rochester)
injected under low pressure into the left ventricular apex until it was
visible in the descending abdominal aorta. Animals were then ﬁxed
for 24 h in 10% buffered formalin, after which the heart and aorta
were stored in 70% ethanol. For immunoblotting analysis, LOX activity
determination, and total collagen and collagen cross-links quantiﬁca-
tion, aorta samples were removed, ﬂash frozen in liquid nitrogen andstored at−80 °C. Samples for RNA isolation were stored in RNAlater
(Sigma Aldrich) and stored at−80 °C until processing.
LOX inhibitor β-aminopropionitrile (BAPN, Sigma-Aldrich) was
dissolved in PBS and administered daily by intraperitoneal injection, at
a dose of 300 mg/kg. Losartan was dissolved in drinking water and ﬁl-
tered to give a concentration of 0.6 g/L, giving an estimated daily dose
of 40–60 mg/kg/day. Placebo groups received PBS (intraperitoneal)
and drinking water, respectively. Treatment was initiated at 6 weeks
of age and continued for 8 weeks.
4.3. Echocardiography
Nair hair removal cream was used on all mice the day prior to
echocardiography. All echocardiograms were performed on awake,
unsedated mice using a Vevo 660 V1.3.6 imaging system (Visualsonics,
Toronto, Canada) and a 30MHz transducer. The aortawas imaged using
a parasternal long axis view. Three separate measurements of the max-
imal internal systolic dimension at the sinus of Valsalva and proximal
ascending aorta were made, and a mean was calculated. All imaging
and measurements were performed by a cardiologist who was blinded
to genotype and treatment arm. Mice were imaged at the beginning of
the treatment (6 weeks of age, baseline), and then 4 and 8 weeks
after BAPN and/or losartan treatment was initiated [25,44].
4.4. Histological and immunohistochemical analysis
The heart and thoracic aorta of the mice were dissected out en bloc.
Transverse sections (2–3 mm long) of the entire thoracic aorta (root,
ascending, transverse, and descending segments) were mounted in 4%
agar prior to parafﬁn-embedding. Segments of human aortic tissues
were directly embedded in parafﬁn wax.
Five-micron sections were stained with Verhoeff–van Gieson (VVG)
for elastin. Slides were examined using an Eclipse T2000U microscope
(Nikon Inc., Tokio, Japan). Four representative VVG images of each
mouse aorta were assessed by 3 blinded observers and graded on a
scale of 1 (indicating no elastic ﬁber breaks) to 4 (indicating extensive
elastic ﬁber fragmentation) as previously described [25]. Tissue sections
were also analyzed for collagen staining with Picrosirius Red (PSR)
under brightﬁeld and polarized light using Leica DM LS2 (Leica
Microsystems, Solms, Germany). The presence of yellowish-orange
birefringent staining under polarized light was taken as an indicative
of mature collagen ﬁbers [45].
For immunohistochemical analysis, cross-sectional slices of parafﬁn-
embedded aortic tissue were deparafﬁnized and counterstained with
hematoxylin using standard protocols. Immunohistochemical stainings
were performed to detect LOX, LOXL1, pSmad2 and pERK1/2. The fol-
lowing primary antibodies were used: anti-LOX (Ab31238, Abcam,
Cambridge, Massachusetts), anti-LOXL1 (sc-166632, Santa Cruz Bio-
technology, Dallas, Texas), anti-Phospho-Smad2 (3101, Cell Signaling
Technology), and anti-Phospho-ERK1/2 (4695S, Cell Signaling Technol-
ogy). Tissue samples were visualized using an Eclipse T2000U (Nikon
Inc.). Quantiﬁcation of stained sections was done by digital image
analysis.
4.5. RNA and protein studies
For RNA extraction, aortic tissue was homogenized in Qiazol (Qiagen,
Venlo, The Netherlands) using an automatic bead homogenizer
(FastPrep24, MP Biomedicals, Carlsbad, California). Medial layer of
human aortic samples were laser microdissected using a PALM Micro-
Beamsystem(Zeiss, Jena, Germany). RNAwas extractedusing chloroform
and precipitated with isopropanol. Transcript levels for the gene of
interest were determined by real-time quantitative reverse transcription
polymerase chain reaction (RT-PCR) using Taqman probes (Applied
Biosystems, Life Technologies, Carlsbad, California) as previously
described [46]. The following prevalidated probes were used to detect
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Mm01145738_m1 (Loxl1), Mm01302039_g1 (Col1a1), Mm01254476_m1
(Col3a1), Mm00439498_m1 (Mmp2), Mm00442991_m1 (Mmp9),
Mm01184417_m1 (Timp4), Hs03929097_g1 (GAPDH), Hs00942480_m1
(LOX), and Hs00935937_m1 (LOXL1). Aortic proteins were extracted
and assayed by immunoblotting using speciﬁc primary antibodies
and species-appropriate secondary antibodies for the LI-COR system
(LI-COR Biosciences, Lincoln, Nebraska).
4.6. LOX activity determination
Aortic tissueswere homogenized in 4Murea in 0.02M borate buffer
(pH 8.0) at 4 °C, and all homogenate was centrifuged at 15,000 g for
30min at 4 °C. The supernatantswere analyzed immediately for LOX ac-
tivity by measuring concomitant H2O2 production using Amplex red
(Life Technologies) as a ﬂuorogenic probe and cadaverine (Sigma-
Aldrich) as LOX substrate, in the presence of horseradish peroxidase
[47]. Fluorescence intensity was determined for test samples with and
without 500 μM BAPN and speciﬁc LOX activity calculated using H2O2
standard and expressed as pmol H2O2/mg protein in 60 min reaction
time.
4.7. Collagen and collagen cross-linking analysis
Aorta tissue portions were hydrolyzed (95 °C, 20 h) in 6 M HCl
and collagen (hydroxyproline) and mature trivalent cross-links,
hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP), analyzed
by a colorimetric assay (Total Collagen Assay, Quickzyme, Leiden,
The Netherlands) and by HPLC, respectively [48]. The amount of colla-
gen and of the cross-link hydroxylysylpyridinoline (HP) is expressed
as μg or pmol per mg wet tissue, respectively.
4.8. Statistical analysis
Data represent mean± SEM. Unpaired 2-tailed Student t tests were
used to determine the signiﬁcance between two groups, assuming sig-
niﬁcance at P b 0.05. Analyses between multiple groups used two-way
ANOVA,with P b 0.05 considered statistically signiﬁcant. Statistical anal-
ysiswas performed usingGraphPad Prism software (La Jolla, California).
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